Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for DVT Prevention in Stented May-Thurner Syndrome
NCT04067505Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in May-Thurner syndrome (MTS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started May 2020; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
May-Thurner syndrome (MTS)
Beyond the preview
Go deeper on NCT04067505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067505.